Press Releases | Insilico Medicine
Aug 13, 2024 · Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI. September 11, 2024.
Insilico Medicine Reports Positive Phase IIa Results for ISM001 …
CAMBRIDGE, Mass., Sept. 18, 2024 /PRNewswire/ -- Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa...
First Generative AI Drug Begins Phase II Trials with ... - Insilico
Insilico Medicine has achieved a new milestone in artificial intelligence drug discovery – bringing the first drug discovered and designed by generative AI into Phase II clinical trials with patients.
Insilico plots pivotal lung disease trial
23 hours ago · Insilico’s AI-designed med tied to respiratory health improvements in midstage lung disease trial. Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a ...
Insilico Medicine Reports Positive Phase IIa Results for ISM001 …
Sep 18, 2024 · Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055.
First Drug Discovered and Designed with Generative AI Enters …
Jun 28, 2023 · Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems.
Novel, AI-Procured ISM001-055 Demonstrates Great Promise for …
1 day ago · Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI. Insilico Medicine. News release.
Insilico Medicine announces positive topline results of ISM001 …
1 day ago · CAMBRIDGE, Mass. — Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced positive topline results from the Phase IIa trial of ISM001-055, the novel drug candidate developed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) for the treatment of idiopathic pulmonary fibrosis (IPF).
Insilico Plans Pivotal Trial for AI-Based IPF Candidate
1 day ago · November 12, 2024. AI-based drug developer Insilico Medicine said today it plans to advance its lead candidate ISM001-055 into a potentially pivotal study, after generating positive topline ...
Insilico Medicine Reports Positive Phase IIa Results for ... - BioSpace
Sep 18, 2024 · Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dose-dependent response in lung function in patients with IPF. ISM001-055’s positive Phase IIa results represent a proof-of-concept success for AI-driven drug discovery.
- Some results have been removed